



## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2012

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2012					
(Rs. in Lakhs)					
Sl. No.	Particulars	3 months ended 30.06.2012	Preceding 3 months ended 31.03.2012	Corresponding 3 months ended 30.06.2011	Previous Year ended 31.03.2012
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>Income from operations</b>				
	a) Net Sales/ Income from Operations (Net of excise duty)	43,160	42,120	33,557	150,480
	b) Other Operating Income	1,584	1,140	1,087	5,105
	<b>Total income from operations (net)</b>	<b>44,744</b>	<b>43,260</b>	<b>34,644</b>	<b>155,585</b>
2	<b>Expenses</b>				
	a) Cost of materials consumed	19,731	19,687	16,424	69,712
	b) Purchases of stock in trade	2,297	2,217	1,764	8,570
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	(689)	(1,057)	(1,812)	(4,142)
	d) Employee benefits expense	5,329	5,124	4,212	19,160
	e) Depreciation and amortisation expenses	2,383	2,421	2,318	9,400
	f) Other expenses	9,678	8,638	6,246	28,930
	<b>Total Expenses</b>	<b>38,729</b>	<b>37,030</b>	<b>29,152</b>	<b>131,630</b>
3	<b>Profit from operations before other income and finance costs (1-2)</b>	<b>6,015</b>	<b>6,230</b>	<b>5,492</b>	<b>23,955</b>
4	Other Income	2,183	1,126	1,664	6,655
5	<b>Profit from ordinary activities before finance costs (3+4)</b>	<b>8,198</b>	<b>7,356</b>	<b>7,156</b>	<b>30,610</b>
6	Finance Costs	56	79	33	170
7	<b>Profit from ordinary activities before tax (5-6)</b>	<b>8,142</b>	<b>7,277</b>	<b>7,123</b>	<b>30,440</b>
8	Tax Expense	1,258	1,047	1,083	4,890
9	<b>Net Profit for the period (7-8)</b>	<b>6,884</b>	<b>6,230</b>	<b>6,040</b>	<b>25,550</b>
10	Paid-up equity share capital (Face Value of Rs.5 each)	10,000	10,000	10,000	10,000
11	Reserve excluding Revaluation Reserves as per balance sheet	-	-	-	199,557
12	<b>Earnings per share (of Rs 5 each) (not annualised)</b>				
	(a) Basic	3.52	3.18	3.09	13.04
	(b) Diluted	3.48	3.15	3.06	12.92
	See accompanying notes to the financial results				
	<b>Select Information for the period</b>				
	<b>PARTICULARS OF SHAREHOLDING</b>				
1	Public Shareholding				
	- Number of Shares	78,175,854	78,175,854	78,165,024	78,175,854
	- Percentage of shareholding	39.09%	39.09%	39.08%	39.09%
2	Promoters and Promoter Group Shareholding				
	a) Pledged/encumbered				
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	121,824,146	121,824,146	121,834,976	121,824,146
	- Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	60.91%	60.91%	60.92%	60.91%

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2012					
(Rs. in Lakhs)					
Sl. No.	Particulars	3 months ended 30.06.2012	Preceding 3 months ended 31.03.2012	Corresponding 3 months ended 30.06.2011	Previous Year ended 31.03.2012
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>Income from operations</b>				
	a) Net Sales/ Income from Operations (Net of excise duty)	57,086	58,922	43,834	204,903
	b) Other Operating Income	582	2,098	514	3,749
	<b>Total income from operations (net)</b>	<b>57,668</b>	<b>61,020</b>	<b>44,348</b>	<b>208,652</b>
2	<b>Expenses</b>				
	a) Cost of materials consumed	22,855	23,545	19,058	81,900
	b) Purchases of stock in trade	2,159	1,786	1,646	7,699
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	(792)	(1,363)	(1,793)	(4,454)
	d) Employee benefits expense	9,127	8,134	6,926	30,761
	e) Depreciation and amortisation expenses	4,269	4,307	4,505	17,442
	f) Other expenses	12,049	14,549	7,317	41,014
	<b>Total Expenses</b>	<b>49,667</b>	<b>50,958</b>	<b>37,659</b>	<b>174,362</b>
3	<b>Profit from operations before other income and finance costs (1-2)</b>	<b>8,001</b>	<b>10,062</b>	<b>6,689</b>	<b>34,290</b>
4	Other Income	1,592	1,222	2,004	6,181
5	<b>Profit from ordinary activities before finance costs (3+4)</b>	<b>9,593</b>	<b>11,284</b>	<b>8,693</b>	<b>40,471</b>
6	Finance Costs	321	300	495	1,223
7	<b>Profit from ordinary activities before tax (5-6)</b>	<b>9,272</b>	<b>10,984</b>	<b>8,198</b>	<b>39,248</b>
8	Tax Expense	1,373	1,204	1,193	5,408
9	<b>Net Profit for the period from continuing operations (7-8)</b>	<b>7,899</b>	<b>9,780</b>	<b>7,005</b>	<b>33,840</b>
10	Net Profit pertaining to discontinued operations (See note 2 below)	-	-	-	-
11	<b>Net Profit for the period (9+10)</b>	<b>7,899</b>	<b>9,780</b>	<b>7,005</b>	<b>33,840</b>
12	Minority interest	19	-	-	-
13	<b>Net Profit after taxes, minority interest (11+12)</b>	<b>7,880</b>	<b>9,780</b>	<b>7,005</b>	<b>33,840</b>
14	Paid-up equity share capital (Face Value of Rs.5 each)	10,000	10,000	10,000	10,000
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				217,165
16	<b>Earnings per share (of Rs 5 each) :</b>				
	(a) Basic	4.02	4.99	3.58	17.27
	(b) Diluted	3.98	4.94	3.55	17.11
	See accompanying notes to the financial results.				
	<b>Select Information for the period</b>				
	<b>PARTICULARS OF SHAREHOLDING</b>				
1	Public Shareholding				
	- Number of Shares	78,175,854	78,175,854	78,165,024	78,175,854
	- Percentage of shareholding	39.09%	39.09%	39.08%	39.09%
2	Promoters and Promoter Group Shareholding				
	a) Pledged/encumbered				
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	121,824,146	121,824,146	121,834,976	121,824,146
	- Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	60.91%	60.91%	60.92%	60.91%

SEGMENT DETAILS OF UNAUDITED CONSOLIDATED RESULTS FOR THE QUARTER ENDED JUNE 30, 2012				
(Rs. in Lakhs)				
Particulars	3 months ended 30.06.2012	Preceding 3 months ended 31.03.2012	Corresponding 3 months ended 30.06.2011	Previous Year ended 31.03.2012
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Segment revenue				
a. Pharma	45,173	48,983	35,428	166,823
b. Contract Research & Manufacturing Services	13,125	12,933	9,578	44,573
<b>Total</b>	<b>58,298</b>	<b>61,916</b>	<b>45,006</b>	<b>211,396</b>
Less : Inter-segment revenue	630	896	658	2,744
<b>Net sales / Income from continuing operations</b>	<b>57,668</b>	<b>61,020</b>	<b>44,348</b>	<b>208,652</b>
Segment results				
Profit before interest, depreciation and tax from each segment				
a. Pharma	17,009	16,001	13,864	61,154
b. Contract Research & Manufacturing Services	4,746	4,589	2,890	14,966
<b>Total</b>	<b>21,755</b>	<b>20,590</b>	<b>16,754</b>	<b>76,120</b>
Less : Interest	321	300	495	1,223
Depreciation and amortisation	4,269	4,307	4,505	17,442
Unallocated corporate expenses	9,485	6,221	5,560	24,388
Unallocated corporate income	(1,592)	(1,222)	(2,004)	(6,181)
<b>Profit before tax from continuing operations</b>	<b>9,272</b>	<b>10,984</b>	<b>8,198</b>	<b>39,248</b>
Capital employed				
a. Pharma	107,731	93,664	112,790	93,664
b. Contract Research & Manufacturing Services	31,426	34,310	24,179	34,310
c. Unallocable	96,442	99,650	74,934	99,650
d. Minority interest	(399)	(380)	-	(380)
e. Discontinued operations (See note 2 below)	-	-	-	-
<b>Total capital employed</b>	<b>235,200</b>	<b>227,244</b>	<b>211,903</b>	<b>227,244</b>

that it has continuing obligations to complete the clinical development and regulatory activities. Accordingly, as at March 31, 2012, Biocon deferred the balance amount of Rs.49,290 Lakhs received from the customer to be recognised in the consolidated statement of profit and loss in subsequent periods in line with costs to be incurred towards such clinical trial and development activities.

In line with this policy, during the quarter ended June 30, 2012, out of the deferred amount, Rs. 1,320 Lakhs has been netted off against expenses incurred during the quarter ended June 30, 2012 towards such clinical trial and development activities.

The auditors of the Company have drawn an Emphasis of Matter in this regard, in their Limited Review report on the consolidated unaudited financial results.

4. The Board of Directors of the Company have approved the scheme of arrangement for merger of Biocon Biopharmaceuticals Limited, a wholly owned subsidiary with the Company, subject to approval of the members and Honorable High Court of Karnataka with an appointed date of April 1, 2012. Pending approval of the relevant authorities, no effect of the above has been given in the standalone financial statements of the Company for the quarter ended June 30, 2012.

5. Segment Reporting:

a. Standalone financial results: The Company operates in a single business segment of biopharmaceuticals.

b. Consolidated financial results: The primary segment reporting has been performed on the basis of business segments. Segments have been identified and reported based on the nature of products, risks and returns, organizational structure and internal financial reporting systems.

6. The figures for the preceding three months ended March 31, 2012 are the balancing figures between the audited figures in respect of the financial year ended March 31, 2012 and the unaudited year to date figures upto December 31, 2011.

7. Prior period / year figures have been reclassified wherever required to conform to the classification of the current period / year.

Sl. No.	Particulars	3 months ended 30.06.2012
<b>B INVESTORS COMPLAINTS</b>		
	Pending at the beginning of the quarter	Nil
	Received during the quarter	36
	Disposed of during the quarter	35
	Remaining unsolved at the end of the quarter	1

#### Notes:

1. The unaudited financial results of the Company and the unaudited consolidated financial results for the three month period ended June 30, 2012 have been subjected to limited review by the statutory auditors. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on July 25, 2012.

2. On April 28, 2011, Biocon SA, a subsidiary of the Company, entered into a definitive agreement with certain third parties to transfer its entire shareholding in the equity capital of its subsidiary, AxiCorp GmbH, Germany ('AxiCorp'), which was consummated during the quarter ended June 30, 2011. The financial results of AxiCorp have been disclosed separately as 'Net Profit pertaining to discontinued operations'. The Company followed a consistent practice of consolidating the financial results of AxiCorp with a gap of 3 months and adjusting for significant subsequent transactions / other events, if any in accordance with Accounting Standard 21. The following table gives the financial information / effect pertaining to the discontinued operations.

Particulars	3 months ended June 30, 2011 (Unaudited)	Previous Year ended March 31, 2012 (Audited)
Net sales/income from operations	24,460	24,460
Profit after tax (Net of Minority Interest)	324	324
Less: Loss of sale of Investment in Subsidiary	324	324
Net Profit attributable to Discontinued operations	-	-

3. In October 2010, Biocon SA, a wholly owned subsidiary of Biocon Limited, (together referred to as 'Biocon'), had entered into a global commercialization and supply agreement ('the Agreement') with a customer. The customer had exclusive rights to commercialize Biocon's biosimilar insulin portfolio. Biocon was responsible for clinical development, clinical trials and other activities to secure regulatory approvals in various geographies. Biocon had received an upfront payment and certain other milestone payments under the Agreement. Considering the significant obligations of Biocon relating to clinical development and regulatory activities, these amounts were recognized in the consolidated statement of profit and loss under percentage completion method. In March 2012, the Agreement was terminated and pursuant to the termination and transition agreement, the exclusive rights to commercialize reverted to Biocon and the customer had no further obligations to Biocon. Biocon is committed to the biosimilar insulins program and is continuing the development / clinical trial activities on a global scale. Biocon evaluated the prevalent regulatory framework, industry practices and ethics/governance requirements relating to clinical trials / regulatory submissions already initiated under the Agreement and determined

For and on behalf of the Board of Directors of Biocon Limited

Sd/-  
**Kiran Mazumdar Shaw**  
Chairman & Managing Director

Place: Bangalore

Date: July 25, 2012